These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 22315133

  • 1. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y, Oshima K, Naoi Y, Nakayama T, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [Abstract] [Full Text] [Related]

  • 2. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [Abstract] [Full Text] [Related]

  • 3. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R.
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [Abstract] [Full Text] [Related]

  • 4. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.
    Cancer; 2011 Aug 15; 117(16):3682-90. PubMed ID: 21305539
    [Abstract] [Full Text] [Related]

  • 5. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.
    PLoS Med; 2007 Mar 15; 4(3):e90. PubMed ID: 17388661
    [Abstract] [Full Text] [Related]

  • 6. 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
    Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z.
    FEBS Lett; 2012 Jan 20; 586(2):163-8. PubMed ID: 22192357
    [Abstract] [Full Text] [Related]

  • 7. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 9. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2000 Jul 04; 6(7):2751-8. PubMed ID: 10914720
    [Abstract] [Full Text] [Related]

  • 10. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.
    Oshima K, Naoi Y, Kishi K, Nakamura Y, Iwamoto T, Shimazu K, Nakayama T, Kim SJ, Baba Y, Tamaki Y, Noguchi S.
    Cancer Lett; 2011 Aug 28; 307(2):149-57. PubMed ID: 21514041
    [Abstract] [Full Text] [Related]

  • 11. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 28; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 12. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
    Kim SJ, Taguchi T, Shimazu K, Tanji Y, Tamaki Y, Noguchi S.
    Oncology; 2009 May 28; 77(2):134-9. PubMed ID: 19628951
    [Abstract] [Full Text] [Related]

  • 13. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.
    Breast Cancer Res Treat; 2012 Sep 28; 135(2):531-7. PubMed ID: 22864769
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L.
    J Clin Oncol; 2010 Feb 10; 28(5):761-6. PubMed ID: 20048189
    [Abstract] [Full Text] [Related]

  • 16. [Neoadjuvant chemotherapy for primary breast cancer].
    Li JF, Ouyang T, Wang TF, Lin BY.
    Zhonghua Zhong Liu Za Zhi; 2004 Aug 10; 26(8):493-5. PubMed ID: 15555342
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.
    Breast Cancer; 2010 Oct 10; 17(4):269-75. PubMed ID: 19730975
    [Abstract] [Full Text] [Related]

  • 18. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2009 Jun 15; 15(12):4234-41. PubMed ID: 19509181
    [Abstract] [Full Text] [Related]

  • 19. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
    de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF.
    Breast Cancer Res Treat; 2013 Jan 15; 137(1):213-23. PubMed ID: 23203637
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
    Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2012 Nov 15; 136(1):107-16. PubMed ID: 22986814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.